Co-Authors
This is a "connection" page, showing publications co-authored by JAMUNARANI VEERARAGHAVAN and CHANDANDEEP NAGI.
Connection Strength
0.317
-
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63.
Score: 0.195
-
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
Score: 0.044
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.041
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.037